You are here

  • Home
  • Archive
  • Volume 22, Issue Suppl 1
  • DI-010 Factors influencing the appearance of haematological and thyroid adverse effects in patients with hepatitis C virus genotype 1 treated with telaprevir/boceprevir plus peg-interferon and ribavirin

Alerts

Article menu
Download PDFPDF
Drug information and pharmacotherapy
DI-010 Factors influencing the appearance of haematological and thyroid adverse effects in patients with hepatitis C virus genotype 1 treated with telaprevir/boceprevir plus peg-interferon and ribavirin
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address